Cargando…

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis

There are no published clinical reports comparing ibandronate (IBN) treatment and zoledronic acid (ZOL) treatment in Japanese postmenopausal osteoporotic patients. This investigation therefore compared the efficacy and safety of the drugs on improving bone metabolism and bone mineral density (BMD) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Uehara, Masashi, Nakamura, Yukio, Suzuki, Takako, Nakano, Masaki, Takahashi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624848/
https://www.ncbi.nlm.nih.gov/pubmed/34830702
http://dx.doi.org/10.3390/jcm10225420
_version_ 1784606274557575168
author Uehara, Masashi
Nakamura, Yukio
Suzuki, Takako
Nakano, Masaki
Takahashi, Jun
author_facet Uehara, Masashi
Nakamura, Yukio
Suzuki, Takako
Nakano, Masaki
Takahashi, Jun
author_sort Uehara, Masashi
collection PubMed
description There are no published clinical reports comparing ibandronate (IBN) treatment and zoledronic acid (ZOL) treatment in Japanese postmenopausal osteoporotic patients. This investigation therefore compared the efficacy and safety of the drugs on improving bone metabolism and bone mineral density (BMD) in Japanese postmenopausal women with primary osteoporosis. Eighty-two treatment-naïve primary osteoporotic female patients were randomly divided into IBN-treated or ZOL-treated groups. Bone turnover markers and BMD were examined immediately prior to treatment (baseline) and at 6, 12, 18, 24, and 30 months of therapy. Compared with baseline levels, the values of type 1 procollagen N-terminal propeptide, bone-specific alkaline phosphatase (BAP), urinary type-I collagen amino-terminal telopeptide (NTX), and tartrate-resistant acid phosphatase 5b were all significantly decreased at every time point in both groups apart from BAP at 30 months in the ZOL group, urinary NTX at 12 months in the ZOL group and at 24 and 30 months in both groups. Lumbar BMD values were significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6 and 12 months in the ZOL group compared with pre-treatment levels. Hip BMD values were also significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6, 12, and 18 months in the ZOL group compared with baseline values. The percentage changes of hip BMD at 18 and 24 months in the ZOL group were significantly higher than those in the IBN group (both p < 0.05). No remarkable adverse events were noted in either group. In conclusion, both IBN and ZOL significantly and safely improved bone turnover markers and BMD during 30 months of treatment in Japanese osteoporosis patients. The ZOL group tended to exhibit greater gains in BMD as compared with the IBN group, which merits further investigation.
format Online
Article
Text
id pubmed-8624848
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86248482021-11-27 Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis Uehara, Masashi Nakamura, Yukio Suzuki, Takako Nakano, Masaki Takahashi, Jun J Clin Med Article There are no published clinical reports comparing ibandronate (IBN) treatment and zoledronic acid (ZOL) treatment in Japanese postmenopausal osteoporotic patients. This investigation therefore compared the efficacy and safety of the drugs on improving bone metabolism and bone mineral density (BMD) in Japanese postmenopausal women with primary osteoporosis. Eighty-two treatment-naïve primary osteoporotic female patients were randomly divided into IBN-treated or ZOL-treated groups. Bone turnover markers and BMD were examined immediately prior to treatment (baseline) and at 6, 12, 18, 24, and 30 months of therapy. Compared with baseline levels, the values of type 1 procollagen N-terminal propeptide, bone-specific alkaline phosphatase (BAP), urinary type-I collagen amino-terminal telopeptide (NTX), and tartrate-resistant acid phosphatase 5b were all significantly decreased at every time point in both groups apart from BAP at 30 months in the ZOL group, urinary NTX at 12 months in the ZOL group and at 24 and 30 months in both groups. Lumbar BMD values were significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6 and 12 months in the ZOL group compared with pre-treatment levels. Hip BMD values were also significantly increased at 6, 12, 18, and 24 months in the IBN group and at 6, 12, and 18 months in the ZOL group compared with baseline values. The percentage changes of hip BMD at 18 and 24 months in the ZOL group were significantly higher than those in the IBN group (both p < 0.05). No remarkable adverse events were noted in either group. In conclusion, both IBN and ZOL significantly and safely improved bone turnover markers and BMD during 30 months of treatment in Japanese osteoporosis patients. The ZOL group tended to exhibit greater gains in BMD as compared with the IBN group, which merits further investigation. MDPI 2021-11-20 /pmc/articles/PMC8624848/ /pubmed/34830702 http://dx.doi.org/10.3390/jcm10225420 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Uehara, Masashi
Nakamura, Yukio
Suzuki, Takako
Nakano, Masaki
Takahashi, Jun
Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_full Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_fullStr Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_full_unstemmed Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_short Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
title_sort efficacy and safety of oral ibandronate versus intravenous zoledronic acid on bone metabolism and bone mineral density in postmenopausal japanese women with osteoporosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624848/
https://www.ncbi.nlm.nih.gov/pubmed/34830702
http://dx.doi.org/10.3390/jcm10225420
work_keys_str_mv AT ueharamasashi efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis
AT nakamurayukio efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis
AT suzukitakako efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis
AT nakanomasaki efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis
AT takahashijun efficacyandsafetyoforalibandronateversusintravenouszoledronicacidonbonemetabolismandbonemineraldensityinpostmenopausaljapanesewomenwithosteoporosis